Defi Technologies Inc (DEFTF)

[TexasMarvL]

In my opinion one wildcard is the Parkinsons Disease test. If AXIM sells a new marketing agreement with a big pharma for the Parkinsons disease test that should come with $$ millions in Up-front revenue and residual revenue for each test.

In my opinion that only happens if AXIM needs the Up-front cash = Now. The Up-front cash would be needed because Cash-flow positive is pushed out with only one new customer per week. It should be obvious to everyone that the Tear-based Point-of-Care quantitative Parkinsons disease test would be a great addition to the Verséa Ophthalmics marketing agreement.

The second wildcard is CLIA Waiver approvals. However it seems like Mr Huemoeller mentioned in so many words that the CLIA Waiver Application has not been started yet. AXIM needs help from Verséa Ophthalmics and/or Mr Kurt Phinney to produce the CLIA Waiver Application and the comparison study.

I guess a third wildcard could be a merger or acquisition.

Outside of a few wildcards AXIM is not cashflow positive for months and months. These are my opinions. I really like the potential I see in AXIM. I may increase my position in AXIM in August or later when funds are hopefully available. The stock price probably does not move until AXIM is closer to cashflow positive.


Good luck to all.
Not investment advice.
Don't invest money needed for food or rent or happiness.